<DOC>
	<DOCNO>NCT00477334</DOCNO>
	<brief_summary>This study evaluate safety efficacy single-day famciclovir episodic treatment Black patient recurrent genital herpes</brief_summary>
	<brief_title>Patient-initiated Episodic Treatment Recurrent Genital Herpes Black Patients</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Black men woman 18 year old History recurrent genital herpes least 4 recurrence precede 12 month precede 12 month prior use suppressive antiviral therapy Documented herpes simplex virus type 2 ( HSV2 ) seropositivity Willingness discontinue suppressive therapy study , applicable Willingness ability comply study protocol Pregnant breastfeed woman Women childbearing potential use accepted method contraception Hypersensitivity famciclovir drug similar chemical structure Renal dysfunction Known suspect decompensated liver disease Known gastrointestinal malabsorption Known immunocompromised Known hypersensitive ingredient study medication Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Recurrent genital herpes</keyword>
	<keyword>Black population</keyword>
</DOC>